Roche Pegasys Once-Weekly Peginterferon Filing Is Set For Early 2000
Executive Summary
Roche expects to file a BLA for its pegylated interferon alpha product Pegasys for hepatitis C in 2000, Roche Clinical Science-Virology Director Joseph Hoffman, MD, reported at a Roche R&D meeting in Basel June 14-15.
You may also be interested in...
Schering Peginterferon European Indication Restricted To Rebetron Failures
Schering-Plough's peginterferon alfa-2b should be used as monotherapy in hepatitis C patients who have failed or are intolerant to ribavirin in interferon-alfa/ribavirin combination therapy (Rebetron), the European Committee for Proprietary Medicinal Products recommends.
Schering Peginterferon European Indication Restricted To Rebetron Failures
Schering-Plough's peginterferon alfa-2b should be used as monotherapy in hepatitis C patients who have failed or are intolerant to ribavirin in interferon-alfa/ribavirin combination therapy (Rebetron), the European Committee for Proprietary Medicinal Products recommends.
Roche Likes Its Critical Mass But Could Amass More; $2 Bil. R&D Will Do
Roche's restructuring and internal growth obviates the need for a merger, even with the recent loss of several late-phase clinical projects, CEO Franz Humer told the Roche 1999 annual earnings conference March 30 in Basel.